secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001193125-23-084515
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA acquires IXINITY royalty and milestone payments from Aptevo for $9.6M
--------------------------------------------------------------------------

- XOMA (US) LLC paid $9.6M to Aptevo for 100% of deferred payments on IXINITY net sales, plus partial milestone payments.
- IXINITY is a hemophilia B treatment marketed by Medexus; purchased receivables stem from a 2020 Aptevo-Medexus sale agreement.
- Additional $50k payment to Aptevo if XOMA receives >$500k of Q1 2023 deferred payments from IXINITY.
- Agreement includes customary covenants, representations, and indemnification provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/0001193125-23-084515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312523084515/d477933d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-084515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer